2008
Persistent Intrathecal Immune Activation in HIV-1-Infected Individuals on Antiretroviral Therapy
Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Persistent Intrathecal Immune Activation in HIV-1-Infected Individuals on Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2008, 47: 168-173. PMID: 17971711, PMCID: PMC2628632, DOI: 10.1097/qai.0b013e31815ace97.Peer-Reviewed Original ResearchConceptsCSF neopterin levelsHIV-1-infected patientsHIV-1-infected individualsCSF neopterin concentrationsCSF viral loadIntrathecal immune activationAntiretroviral therapyHIV-1 RNACopies/mLNeopterin levelsViral loadNeopterin concentrationsImmune activationCSF HIV-1 RNA loadMost HIV-1-infected individualsPlasma HIV-1 RNA levelsCerebrospinal fluid (CSF) neopterin levelsQuantitative HIV-1 RNAHIV-1 RNA levelsHIV-1 RNA loadCell-mediated immune responsesHIV-1 RNA quantificationHIV-1 concentrationsStable antiretroviral therapySuppressive antiretroviral therapy
2006
Treatment Benefit on Cerebrospinal Fluid HIV‐1 Levels in the Setting of Systemic Virological Suppression and Failure
Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Treatment Benefit on Cerebrospinal Fluid HIV‐1 Levels in the Setting of Systemic Virological Suppression and Failure. The Journal Of Infectious Diseases 2006, 194: 1686-1696. PMID: 17109340, DOI: 10.1086/508750.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCSF HIV-1 RNA levelsPlasma HIV-1 RNA levelsRNA levelsAntiretroviral therapyCSF inflammationCopies/Successful therapyPlasma HIV-1 RNA assaysHIV-1 RNA assaysHIV-1-infected subjectsSuppressive combination antiretroviral therapyDrug resistanceHIV-1 levelsCombination antiretroviral therapyHIV-negative subjectsGenotypic resistance testingFailure of therapyHuman immunodeficiency virusCopies/mLSubset of subjectsActive neurological diseaseCross-sectional analysisVirological suppressionImmunodeficiency virus